Bouras T, Sgouros S Complications of endoscopic third ventriculostomy. J Neurosurg Pediatr. 2011 Jun;7(6):643-9. doi: 10.3171/2011.4.PEDS10503. Review.
Breimer GE, Sival DA, Brusse-Keizer MG, Hoving EW An external validation of the ETVSS for both short-term and long-term predictive adequacy in 104 pediatric patients. Childs Nerv Syst. 2013 Aug;29(8):1305-11. doi: 10.1007/s00381-013-2122-8. Epub 2013 May 5.
Dewan MC, Lim J, Shannon CN, Wellons JC 3rd The durability of endoscopic third ventriculostomy and ventriculoperitoneal shunts in children with hydrocephalus following posterior fossa tumor resection: a systematic review and time-to-failure analysis. J Neurosurg Pediatr. 2017 May;19(5):578-584. doi: 10.3171/2017.1.PEDS16536. Epub 2017 Mar 10. Review.
Dlouhy BJ, Capuano AW, Madhavan K, Torner JC, Greenlee JD Preoperative third ventricular bowing as a predictor of endoscopic third ventriculostomy success. J Neurosurg Pediatr. 2012 Feb;9(2):182-90. doi: 10.3171/2011.11.PEDS11495.
Durnford AJ, Kirkham FJ, Mathad N, Sparrow OC Endoscopic third ventriculostomy in the treatment of childhood hydrocephalus: validation of a success score that predicts long-term outcome. J Neurosurg Pediatr. 2011 Nov;8(5):489-93. doi: 10.3171/2011.8.PEDS1166.
Dusick JR, McArthur DL, Bergsneider M Success and complication rates of endoscopic third ventriculostomy for adult hydrocephalus: a series of 108 patients. Surg Neurol. 2008 Jan;69(1):5-15.
Faggin R, Calderone M, Denaro L, Meneghini L, d'Avella D Long-term operative failure of endoscopic third ventriculostomy in pediatric patients: the role of cine phase-contrast MR imaging. Neurosurg Focus. 2011 Apr;30(4):E1. doi: 10.3171/2011.1.FOCUS10303.
Foley RW, Ndoro S, Crimmins D, Caird J Is the endoscopic third ventriculostomy success score an appropriate tool to inform clinical decision-making? Br J Neurosurg. 2017 Jun;31(3):314-319. doi: 10.1080/02688697.2016.1229744. Epub 2016 Sep 14.
Gliemroth J, Käsbeck E, Kehler U Ventriculocisternostomy versus ventriculoperitoneal shunt in the treatment of hydrocephalus: a retrospective, long-term observational study. Clin Neurol Neurosurg. 2014 Jul;122:92-6. doi: 10.1016/j.clineuro.2014.03.022. Epub 2014 Mar 26.
Grand W, Leonardo J, Chamczuk AJ, Korus AJ Endoscopic Third Ventriculostomy in 250 Adults With Hydrocephalus: Patient Selection, Outcomes, and Complications. Neurosurgery. 2016 Jan;78(1):109-19. doi: 10.1227/NEU.0000000000000994.
Hong S, Hirokawa D, Usami K, Ogiwara H The long-term outcomes of endoscopic third ventriculostomy in pediatric hydrocephalus, with an emphasis on future intellectual development and shunt dependency. J Neurosurg Pediatr. 2018 Oct 12;23(1):104-108. doi: 10.3171/2018.7.PEDS18220.
Labidi M, Lavoie P, Lapointe G, Obaid S, Weil AG, Bojanowski MW, Turmel A Predicting success of endoscopic third ventriculostomy: validation of the ETV Success Score in a mixed population of adult and pediatric patients. J Neurosurg. 2015 Dec;123(6):1447-55. doi: 10.3171/2014.12.JNS141240. Epub 2015 Jul 24.
Merkler AE, Ch'ang J, Parker WE, Murthy SB, Kamel H The Rate of Complications after Ventriculoperitoneal Shunt Surgery. World Neurosurg. 2017 Feb;98:654-658. doi: 10.1016/j.wneu.2016.10.136. Epub 2016 Nov 5.
Vogel TW, Bahuleyan B, Robinson S, Cohen AR The role of endoscopic third ventriculostomy in the treatment of hydrocephalus. J Neurosurg Pediatr. 2013 Jul;12(1):54-61. doi: 10.3171/2013.4.PEDS12481. Epub 2013 May 17.
Vulcu S, Eickele L, Cinalli G, Wagner W, Oertel J Long-term results of endoscopic third ventriculostomy: an outcome analysis. J Neurosurg. 2015 Dec;123(6):1456-62. doi: 10.3171/2014.11.JNS14414. Epub 2015 Jul 31.
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.
